{Reference Type}: Journal Article
{Title}: Translating NIA-AA criteria into usual practice: Report from the ReDeMa Project.
{Author}: Sánchez-Soblechero A;Berbel A;Villarejo A;Palmí-Cortés I;Vieira A;Gil-Moreno MJ;Fernández C;Martín-Montes Ã;Carreras MT;Fernández Y;Puertas C;Blanco-Palmero V;Llamas S;González-Sánchez M;Lapeña T;de Luis P;Manzano S;Olazarán J;
{Journal}: Alzheimers Dement (N Y)
{Volume}: 10
{Issue}: 1
{Year}: 2024 Jan-Mar
暂无{DOI}: 10.1002/trc2.12451
{Abstract}: BACKGROUND: Biomarker-informed criteria were proposed for the diagnosis of Alzheimer's disease (AD) by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2011; however, the adequacy of this criteria has not been sufficiently evaluated.
METHODS: ReDeMa (Red de Demencias de Madrid) is a regional cohort of patients attending memory and neurology clinics. Core cerebrospinal fluid biomarkers were obtained, NIA-AA diagnostic criteria were considered, and changes in diagnosis and management were evaluated.
RESULTS: A total of 233 patients were analyzed (mean age 70 years, 50% women, 73% AD). The diagnostic language was modified significantly, with a majority assumption of NIA-AA definitions (69%). Confidence in diagnosis increased from 70% to 92% (p < 0.0005) and management was changed in 71% of patient/caregivers. The influence of neurologist's age or expertise on study results was minimal.
CONCLUSIONS: The NIA-AA criteria are adequate and utile for usual practice in memory and neurology clinics, improving diagnostic confidence and significantly modifying patient management.
CONCLUSIONS: Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers increase diagnostic certainty regardless of the neurologist.AD CSF biomarkers lead to changes in disease management .Biomarker-enriched, 2011 NIA-AA diagnostic criteria are adequate for usual practice.